What is the price of dacomitinib/dacomitinib per box in 2024?

Dacomitinib/Dacomitinib (Dacomitinib), as a second-generation irreversible EGFR tyrosine kinase inhibitor, is regarded as a pan-ErbB inhibitor due to its broad inhibitory effect on ErbB family members.

Dacomitinib has been approved as a first-line treatment for patients with non-small cell lung cancer who have EGFR activating mutations because it showed more significant efficacy compared with gefitinib in non-small cell lung cancer patients. In addition, dacomitinib is expected to be used in combination with conventional chemotherapy or other monoclonal antibodies targeting the EGFR receptor to further enhance the therapeutic effect. It is worth mentioning that dacomitinib has shown brain penetration in preclinical studies, which provides new treatment possibilities for patients with CNS metastases. At the same time, for patients who are resistant to osimertinib first-line treatment, the efficacy of dacomitinib as a second-line treatment is also being evaluated.

In the domestic market, the original drug dacomitinib is already available and has been included in the Category B medical insurance drug list, which undoubtedly brings hope to many patients. Currently, a box of 15mg*30 tablets of dacomitinib is sold domestically for about more than 1,000 yuan, which is relatively affordable. However, in overseas markets, especially the European market, the price of dacomitinib with the same specifications is as high as more than 20,000 yuan, and the price is also affected by exchange rate fluctuations.

Fortunately, more affordable generic drug options also exist in overseas markets. For example, a dacomitinib generic drug produced in Laos has the specification of 45mg*30 tablets and the price is only about 800 yuan. Although the price may fluctuate due to exchange rate changes, its price advantage is still very obvious compared to the original drug. This undoubtedly provides a more economical option for patients who need to take dacomitinib for a long time.